| Literature DB >> 27447671 |
Laura Fernández-García1, Lucia Blasco2, Maria Lopez3,4, German Bou5,6, Rodolfo García-Contreras7, Thomas Wood8,9, María Tomas10,11.
Abstract
Toxin-antitoxin (TA) systems are prevalent in bacteria and archaea. Although not essential for normal cell growth, TA systems are implicated in multiple cellular functions associated with survival under stress conditions. Clinical strains of bacteria are currently causing major human health problems as a result of their multidrug resistance, persistence and strong pathogenicity. Here, we present a review of the TA systems described to date and their biological role in human pathogens belonging to the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) and others of clinical relevance (Escherichia coli, Burkholderia spp., Streptococcus spp. and Mycobacterium tuberculosis). Better understanding of the mechanisms of action of TA systems will enable the development of new lines of treatment for infections caused by the above-mentioned pathogens.Entities:
Keywords: Toxin-Antitoxin; chromosome; clinical; pathogens; persistance; plasmids; resistance; virulence
Mesh:
Substances:
Year: 2016 PMID: 27447671 PMCID: PMC4963858 DOI: 10.3390/toxins8070227
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Models representing the interaction between toxins and antitoxins in the different types of toxin-antitoxin (TA) systems. (A) Type I: the antitoxin mRNA binding to toxin mRNA, which prevents toxin protein formation; (B) type II: a TA complex is formed by the union of toxin and antitoxin proteins; (C) type III: a TA complex is formed by the union of toxin protein with antitoxin mRNA; (D) type IV: the antitoxin protein binds to the toxin target, blocking its action; (E) type V: the antitoxin mRNA encodes an RNAse that degrades the toxin mRNA.
Role of different types of TA (Toxin-antitoxin) systems in clinical pathogens. ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) and other pathogens of clinical interest.
| Bacterium | TA System | Type | Localization | Function | Other Pathogens | References |
|---|---|---|---|---|---|---|
| ESKAPE Group | ||||||
| Par locus | I | Plasmid pAD | Regulation, persistence and plasmid maintenance | [ | ||
| Axe/Txe | II | Plasmid pRUM | Plasmid maintenance and vancomycin resistance (VanA enzyme) | [ | ||
| Omega/Epsilon/Zeta | II | Plasmid pVEF3 | Plasmid maintenance vancomycin resistance (VanA enzyme) | [ | ||
| HigBA | II | Chromosome | Expression of virulence factors | [ | ||
| MazEF | II | Chromosome | Expression of virulence factors | [ | ||
| PemIK | II | Plasmid cCHP91 | Plasmid maintenance and global regulation of virulence | - | [ | |
| SprG1/Spr1 | II | Phage | Lytic activity (human erythrocytes) | - | [ | |
| SprA1 (PepA1/AS) | I | Pathogenicityisland/Chromosome | Persistence and pathogenicity | - | [ | |
| MazEF | II | Chromosome | Regulation of β-lactamase sensitivity | [ | ||
| YefM/YoeB | II | Chromosome | Cell arrest | - | [ | |
| Omega/Epsilon/Zeta | Chromosome | - | [ | |||
| RelBE_1 | II | Plasmid | Persistence of cells against antibiotics and plasmid maintenance | A. | [ | |
| RelBE_2 | II | Chromosome | ||||
| RelBE, HigBA, SplTA and CheTA | II | Plasmid p3ABAYE | Plasmid maintenance | [ | ||
| AbKAB (SplTA) | II | Plasmid | Plasmid maintenance and carbapenem resistance (OXA 24 ß-lactamase) | [ | ||
| GraTA | II | Plasmid | - | [ | ||
| MazEF | II | Chromosome | - | [ | ||
| ParAB, TOX1/TOX2, T/AT1-2 | II | Plasmid pNOR-2000 | Plasmid maintenance and carbapenem resistance(VIM metallo-ß-lactamase) | [ | ||
| RelBE | II | Chromosome | - | [ | ||
| HigBA | II | Chromosome/ Plasmid Rts1 | Reduction of pyochelin, swarming and biofilm formation | [ | ||
| GraTA | II | Chromosome | Persistence | [ | ||
| MazEF | II | Chromosome | Persistence | [ | ||
| Vap-type systems | II | - | Regulation of virulence | [ | ||
| YefM/YoeB | II | Chromosome | Regulation of virulence | [ | ||
| Hha/TomB | II | Chromosome | Regulation of virulence | [ | ||
| PasTI | II | Chromosome | Regulation of virulence | [ | ||
| - | - | - | - | - | ||
| PemIK, VagCD, CcdAB, Hok/Sok, ParAB and PsiAB | II | Plasmid pEC302104 | Plasmid maintenance and ß-lactam resistance (ESBL ß-lactamase) | [ | ||
| TisB/IstR | I | Chromosome | Regulation of SOS response | - | [ | |
| SymER | I | Chromosome | Regulation of SOS response | - | [ | |
| MazEF | II | Chromosome | Persistence, biofilm formation | [ | ||
| RelBE | II | Chromosome | Persistence, biofilm formation | [ | ||
| YefM/YoeB | II | Chromosome | Persistence, biofilm formation | [ | ||
| MqsRA | II | Chromosome | Influence on biofilm formation and global stress response. Control of GhoTS System. Increased tolerance to bile acid. | - | [ | |
| GhoTS | V | Chromosome | Persistence, biofilm formation | - | [ | |
| Hha/TomB | II | Chromosome | Persistence, decreases biofilm formation by inhibiting fimbriae production. | [ | ||
| PasTI | II | - | Persistence | [ | ||
| TAS1/TAS2 | II | Plasmid pC3 | Plasmid maintenance and tolerance to antibiotics | - | [ | |
| RelBE | II | Chromosome | Persistence | [ | ||
| HicAB | II | Chromosome | Persistence | [ | ||
| YefM/YoeB | II | - | Implicated in pathogenicity, phase variation, genetic competence, biofilm formation and bistability | [ | ||
| PezAT | II | - | Persistence and biofilm formation | - | ||
| RelBE | II | Chromosome | Associated with survival and human colonization | [ | ||
| Phd-Doc | - | - | - | [ | ||
| YefM/YoeB | II | Chromosome | Persistence | [ | ||
| RelBE | II | Chromosome | Persistence | [ | ||
| ParDE | II | Chromosome | Persistence | - | [ | |
| HigBA | II | Chromosome | Persistence | [ | ||
| TAC | Chromosome | - | - | [ | ||
| MazEF | II | Chromosome | Persistence and cell arrest | [ | ||
| VapBC | II | Chromosome | Persistence | [ | ||
Figure 2Model of MazEFSa regulation. Transcription of the operon mazES-rsbUVW-sigB is initiated by the mazEF promoter, and transcription of the rsbUVW-sigB genes depends on the activity of the transcriptional terminator downstream of the mazE and mazF genes. This system is negatively regulated by the σB, encoded by sigB, which represses the mazEF promoter. Toxin MazF is an RNAse that degrades the mRNA in the UACAU site. The antitoxin MazE binds and inactivates the toxin MazF. This system is negatively regulated by the σB encoded by sigB.